Fig. 1From: Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trialFlow chart illustrating the treatment schedule for enrolled patientsBack to article page